On July 2023, SOPHiA GENETICS, a leading data-driven medicine company, has announced that the Centre Hospitalier de Bastia, a general hospital in Bastia, Corsica, has implemented the SOPHiA DDM™ Platform. The platform will facilitate in-house next-generation sequencing (NGS) and support clinical oncology research, particularly in the field of hematologic malignancies. Hematologic cancers, including leukemia, lymphoma, and myeloma, originate in the immune system or blood-forming tissue. These types of cancers are prevalent and can progress rapidly.
The SOPHiA DDM™ Platform, a cloud-based solution incorporating Artificial Intelligence (AI) and patented technologies, enables the analysis of NGS data and the identification of disease-related mutations. By adopting this platform, Centre Hospitalier de Bastia aims to enhance its molecular testing capabilities, develop in-house expertise, and expedite research on hematologic malignancies, as well as other cancer types.
Implementing the SOPHiA DDM™ Platform will enable Centre Hospitalier de Bastia to streamline testing and reporting processes across its various units and the public health department. This synchronization will enhance the efficiency of data analysis and empower researchers to practice data-driven medicine effectively.